Wilke, C.

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Rugo, H. S., André, F., Yamashita, T., Cerda, H., Toledano, I., Stemmer, S. M., Jurado, J. C., Juric, D., Mayer, I., Ciruelos, E. M., et al. (2020) · Annals of Oncology

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 193

Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

Juric, D., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H., Iwata, H., Conte, P., Mayer, I., Kaufman, B., et al. (2019) · Cancer Research

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 62